Journal of Pharmaceutical Practice and Service 2025;43(12):591-598
doi:10.12206/j.issn.2097-2024.202302020
Mechanism of Xiakucao Xiaoliu Mixture against non-small cell lung cancer by network pharmacology
Yue HU 1 ; Yong YIN 2 ; Liuhui SHI 2 ; Xiaohong XU 1 ; Jianyong ZHU 1 ; Hua NIAN 1
Affiliations
Keywords
Xiakucao Xiaoliu Mixture; non-small cell lung cancer; network pharmacology; mechanism of action
Country
China
Language
Chinese
Abstract
Objective To explore the mechanism of Xiakucao Xiaoliu Mixture against non-small cell lung cancer (NSCLC). Methods The effective components of Xiakucao Xiaoliu Mixture were screened by TCMSP, BATMAN-TCM database and literature reviews. The targets of effective components were predicted. NSCLC related targets were collected by GeneCards, OMIM, PharmGKB, TTD and Drugbank, combined with the differential genes of Xiakucao Xiaoliu Mixture against Lewis lung cancer mice. The intersection targets of Xiakucao Xiaoliu Mixture against NSCLC were obtained. Cytoscape software was used to construct the network diagram of traditional Chinese medicine-active ingredients-core targets. STRING database was used to construct PPI network diagram. GO function enrichment analysis and KEGG pathway enrichment analysis of the intersection targets were performed by Metascape database to predict the key targets and active components of Xiakucao Xiaoliu Mixture against NSCLC, and Schrodinger software was used to perform molecular docking verification. Results The 32 active components and 24 intersection targets of Xiakucao Xiaoliu Mixture against NSCLC were obtained. 11 core targets such as ESR1, MAPK1 were found. The mechanism of action may be related to 30 signaling pathways such as cellular senescence, receptor activation, prolactin signaling pathway. Conclusion The active components of Xiakucao Xiaoliu Mixture act on multiple targets and signaling pathways to regulate complex biological processes. By regulating ESR1 agsinst NSCLC, it may play an important role in improving the survival rate and prognosis of female patients.
备案号: 11010502037788, 京ICP备10218182号-8)